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Background: To prospectively determine health status and health utility and its predictors in patients with multiple
sclerosis (MS).
Methods: A total of 144 MS patients (mean age: 41.0 ±11.3y) with different subtypes (patterns of progression) and
severities of MS were recruited in an outpatient university clinic in Germany. Patients completed a questionnaire at
baseline (n = 144), 6 months (n = 65) and 12 months (n = 55). Health utilities were assessed using the EuroQol
instrument (EQ-5D, EQ VAS). Health status was assessed by several scales (Expanded Disability Severity Scale (EDSS),
Modified Fatigue Impact Scale (M-FIS), Functional Assessment of MS (FAMS), Beck Depression Inventory (BDI-II) and
Multiple Sclerosis Functional Composite (MSFC)). Additionally, demographic and socioeconomic parameters were
assessed. Multivariate linear and logistic regressions were applied to reveal independent predictors of health status.
Results: Health status is substantially diminished in MS patients and the EQ VAS was considerably lower than that of
the general German population. No significant change in health-status parameters was observed over a 12-months
period. Multivariate analyses revealed M-FIS, BDI-II, MSFC, and EDSS to be significant predictors of reduced health status.
Socioeconomic and socio-demographic parameters such as working status, family status, number of household
inhabitants, age, and gender did not prove significant in multivariate analyses.
Conclusion: MS considerably impairs patients’ health status. Guidelines aiming to improve self-reported health status
should include treatment options for depression and fatigue. Physicians should be aware of depression and fatigue as
co-morbidities. Future studies should consider the minimal clinical difference when health status is a primary outcome.
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Multiple sclerosis (MS) is a demyelinating autoimmune
disease and a common cause of severe neurological dis-
ability in young adults in the Western world, presenting
with diverse and often unpredictable symptoms and an
uncertain course of progression. According to recent esti-
mates, 1.3 million patients suffer from MS worldwide with
0.08-0.13% of the German population being affected [1-3].
The subtypes are defined by their pattern of progression;
approximately 10-20% of MS patients suffer from primary
progressive disease (PPMS), which has a slightly later on-
set compared to the other subtypes. The long-term prog-
nosis remains generally poor; 15 years after diagnosis, over* Correspondence: dodel@med.uni-marburg.de
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reproduction in any medium, provided the or80% of patients have functional and/or cognitive limita-
tions and 50-60% require assistance to walk.
Health status (HS) in MS has been intensively studied in
the past two decades and approximately 20 disease-
specific health- status measures have been developed [4].
Predictors of health status reveal that physical and psycho-
logical symptoms are interrelated and that both are im-
portant. Depression is one of the strongest psychiatric
predictors of poor health, as well as cognitive impairment
and fatigue (for a review see e.g. [5]).
Psychological and behavioural symptoms have long been
disregarded and undertreated in patients with MS [6]. The
burden of living with MS affects physical and mental
health and has negative effects on work life [7]. Neuro-
psychiatric symptoms such as fatigue present early in the
course of disease, and specific cognitive impairments cantd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stages [8,9]. Even in patients with short (less than 2 years)
disease durations, discrete impairment of cognitive func-
tion may be observed in up to 60% of patients upon neuro-
psychological testing [10]. Symptoms of depression also
present early in the course of disease and affect cognitive
performance. Within a year of diagnosis, 48% of patients
and 46% of their relatives show clinically relevant anxiety,
depression or distress [11,12].
Therapies that are newly available or undergoing clinical
trials may place an economic strain on health-care sys-
tems. Therefore, one important aspect in the appraisal of
new treatments is the effectiveness at improving health
status.
The aim of this study was to systematically explore fac-
tors associated with MS and their contribution to de-
creases in patient-reported health status. To address this
question, we used a longitudinal study design in which pa-
tients were repeatedly questioned over a 12-month period.
We used the EuroQoL (EQ-5D) instrument and its Visual
Analogue Scale (EQ VAS) [13] as well as the disease-




Patients were recruited in the Department of Neur-
ology, Philipps-University Marburg from October to
December 2007 for baseline assessments. A conveni-
ence sample was recruited from 186 patients admitted
to the Department of Neurology during that time.
77.4% of these patients participated. Patients were in-
cluded if they fulfilled the McDonald diagnostic criteria
for MS [15,16]. The case report form (CRF) consisted of
two parts: one to be completed by the examining phy-
sician and one to be completed by the patient. Patients
could complete their part of the CRF during their hos-
pital stay or return it later by mail. Patients were
assessed three times: at baseline (n = 144) and at follow-
up assessments after 6 (n = 65) and 12 months (n = 55).
The local ethics committee of Philipps-University
Marburg approved this study and all patients gave writ-
ten consent prior to participation.
Measurements
The questionnaire consisted of an evaluation of the
socio-demographic, clinical, and health status of patients
suffering from MS. In addition, health-care resource uti-
lisation for MS and indirect costs were examined.
In the patients’ part of the CRF, health status was first
evaluated by an MS-specific measure: the Functional As-
sessment of MS (FAMS) which consists of four subscales
covering mobility (“I have trouble walking”), symptoms
(“I have pain”), emotional well-being (“I am able to enjoylife”), and general contentment (“I have accepted my illness”)
with seven items each and scores ranging from 0 (poor
QoL) to 28 (high QoL), as well as a thinking-and-fatigue
subscale (“I feel tired”) that contains 8 items and is scored
from 0 to 36. The FAMS sum score has a maximum score
of 172 [14].
Second, health status was measured by the generic
EuroQoL instrument. Applicable to a wide range of
health conditions and treatments, EQ-5D generates a
health profile, but is also capable of expressing health
status as a single index value (utility value). Thus, it
can be used for clinical and economical evaluations of
health care. The questionnaire consists of five ques-
tions representing five different dimensions (“Mobi-
lity”, “Self-Care”, “Usual Activities”, “Pain/Discomfort”,
and “Anxiety/Depression”). An index score can be de-
rived by time-trade-off methods based on a recent
European study [13]. The second part of the EuroQol
instrument consists of a visual analogue scale (EQ
VAS) on which respondents rate their subjective health
status on a scale from 0 (poorest) to 100 (best imagi-
nable) [13].
The impact of fatigue was assessed using the Modified
Fatigue Impact Scale (M-FIS) [17]. The scale consists of 21
items, with 10 items related to mental fatigue and 11 items
related to physical and social fatigue. The scoring ranges
between 0 and 82, with higher scores reflecting greater
impact. In the literature, a cut-off value of 38 has been used
to distinguish fatigued from non-fatigued patients [18,19].
In addition, depression was assessed using the Beck De-
pression Inventory (BDI-II), a 21-item scale used to mea-
sure self-reported severity of depression. According to
common conventions, the BDI sum score was categorised
into five groups: no (0–8 points), minimal (9–13 points),
mild (14–19 points), moderate (20–28 points), and severe
(>28 points) depressive symptoms [20,21].
The second part of the CRF was to be completed by
the examining physician and concerned the pattern of
progression (MS subtype), comorbidities, neuropsychi-
atric symptoms, and the assessment of disease severity
by the Expanded Disability Status Scale (EDSS) [22] and
the MS Functional Composite (MSFC) [23].
The EDSS is an MS-specific scale consisting of a
neurological assessment quantifying disability in eight
functional systems (e.g., sensory functions, cerebellar
functions). The assessment of these functional systems
yields a sum score ranging from 0 (no neurological im-
pairment) to 10 (death due to MS) [24].
The MS Functional Composite (MSFC) comprises
quantitative functional measures of three key clinical di-
mensions of MS: leg function/ambulation, arm/hand
function, and cognitive function. Scores on component
measures are converted to standard scores (z-scores),
which are averaged to yield a single MSFC score [25].
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Results are presented as means ± SD and median or per-
centages as appropriate. Groups were compared by the
appropriate parametric and nonparametric tests (t-test,
Mann–Whitney-U test, Kruskall-Wallis test). The base-
line investigation and the follow-up investigations were
compared using repeated-measures analysis of variance.
Missing values were handled by pairwise deletion. The
potential changes in the five EQ-5D domains were
analysed using univariate repeated-measurement tests.
Variables were screened for impact on health status
using the Spearman rank correlation (p = 0.10). From
the variables that proved significant in bivariate analyses,
reasonable variables were chosen for multiple linear re-
gression with EQ VAS, EQ-5D index score, and FAMS
sum score as dependent variables. We used a stepwise
forward mode to include independent predictors with a
significance level of α=0.05. Uni- and multivariate logis-
tic regression analyses were applied to test for significant
predictors of single dimensions of the EQ-5D index. The
variables for the five dimensions were dichotomised into
“having problems” or “having no problems” (e.g., “no
problems with daily activities” was represented as 0,
“some problems” or “severe problems with daily acti-
vities” was represented as 1). Statistical analyses were
performed with the SPSS 19.0 software package (IBM
Inc., Armonk, NY.).
Results
Clinical and socio-demographic characteristics
A total of 144 MS patients were evaluated in this study:
99 women (68.3%) and 45 men (31.7%). At the 6-month
follow-up, 65 patients remained in the study; at the
12-month follow-up, 55 patients remained. Furthermore,Table 1 Demographic and clinical data of the study sample a
Variable RRMS SPM
% (n) % (n
Females % (n) 67.7 (63) 29.1
Males % (n) 65.9 (29) 25.0
Mean (SD) Mea
Age (years) 36.4 (9.7) 50.4
Disease duration (years) 5.3 (5.1) 13.6
MSFC Z-composite score 0.100 (0.632) −0.6
M-FIS sum score 33.2 (20.4) 44.1
FAMS sum score 120.3 (33.2) 101
EQ-5D index score 0.83 (0.18) 0.64
EQ VAS 68.4 (18.2) 50.6
BDI sum score 14.7 (10.2) 14.5
EDSS score 2.6 (1.5) 5.4 (
MSFC: Multiple Sclerosis Functional Composite, M-FIS: Modified Fatigue Impact Scal
Visual Analogue Scale, BDI: Beck Depression Inventory II, EDSS: Extended Disability7 patients did not complete the demographic question-
naire at baseline and were therefore excluded from fur-
ther analyses. The patients’ demographic and clinical
data are presented in Table 1.
Most of the patients lived with partners (76.1%); 45%
had a secondary school education (or higher); and 38%
stated that their career advancement was impaired by
MS. In addition, 37% claimed that due to the disease,
they earned less than their unaffected colleagues.
Health status
At baseline, the distribution of patients among the dif-
ferent subtypes of MS was as follows: 66.8% relapsing-
remitting multiple sclerosis (RRMS), 27% secondary
progressive multiple sclerosis (SPMS), and 6.2% pri-
mary progressive multiple sclerosis (PPMS). Within
the 12-months observation period, the median EDSS
score increased from 3.50 (range 0 to 8.5) to 4.00
(range 0 to 9.00) with 60.3% of patients progressing
to higher EDSS stages. The mean total MSFC z-score
improved minimally, from −0.100 (SD: 0.741) to 0.199
(SD: 0.682) during the 12-month observation period
(Table 2). SPMS and PPMS patients were older and
had worse disability scores (EDSS and MSFC, Table 1)
than RRMS patients at baseline.
The PPMS group was the most impaired group by fa-
tigue and depression. Clinically relevant depressive symp-
toms, as measured by BDI-II, were very common in the
study population (Table 2). In all, 61 patients (41.5%)
had depressive symptoms (BDI sum score >13pts); 12
(8.2%) thereof had severe depressive symptoms at
baseline. Depressive symptoms were significantly posi-
tively correlated with Expanded Disability Status
(Jonckheere-Terpstra J = 5163, z = 284.7, r = 23.7, p =t baseline (n = 137)
S PPMS Total
) % (n) % n
(27) 3.2 (3) 100 (93)
(11) 9.1 (4) 100 (44)
n (SD) Mean (SD) Mean (SD )
(8.9) 50.5 (10.4) 41.1 (11.3)
(8.1) 8.3 (11.7) 7.3 (7.2)
70 (0.654) −0.882 (1.128) - 0.121 (0.750)
(13.7) 40.6 (15.2) 36.4 (18.6)
.7 (26.3) 98.1 (27.6) 113.3 (32.4)
(2.78) 0.64 (0.26) 0.77 (0.23)
(18.4) 44.8 (20.1) 62.0 (20.5)
(8.6) 16.2 (11.2) 14.7 (10.4)
1.5) 5.9 (1.2) 3.5 (2.0)
e, FAMS: Functional Assessment in Multiple Sclerosis, EQ-5D: EuroQoL, EQ VAS:
Symptom Scale; SD: standard deviation.
Table 2 Clinical characteristics of patients with multiple sclerosis included in this study and results of EDSS, EQ-5D,
FAMS, MSFC, M-FIS, and BDI-II at baseline, 6 months and 12 months follow-up investigation
Variable Baseline 6 months Δ Baseline – 6 M 12 months Δ Baseline – 12 M
Median (range) Median (range) p-value Median (range) p-value
Mean ± SD Mean ± SD p-value Mean ± SD p-value
EDSS (N = 55) 3.50 (0–8.5) 3.25 (0–8.0) n.s. 4.0 (0–9.0) <0.001
EuroQol
EQ-5D Index Score (N = 56) 0.79 ±0.20 0.79 ±0.19 n.s. 0.78 ±0.23 n.s.
EQ VAS (N = 51) 59.84 ±20.0 61.82 ±18.7 n.s. 61.37 ±18.4 n.s.
FAMS (N = 56)
Sum Score 113.7 ±32.3 115.1 ± 31.6 n.s. 110.3 ± 31.6 n.s.
Mobility 16.7 ±7.1 16.4 ± 7.0 n.s. 15.7 ± 7.1 n.s.
Symptoms 20.1 ±5.6 20.3 ± 5.3 n.s. 20.1 ± 5.2 n.s.
Emotional Well-being 19.3 ±6.2 19.8 ± 6.0 n.s. 18.9 ± 6.1 n.s.
General Contentment 17.2 ±6.6 17.5 ± 6.2 n.s. 16.8 ± 5.9 n.s.
Thinking and Fatigue 21.0 ±9.1 21.4 ± 9.2 n.s. 19.3 ± 9.6 n.s.
Family/ Social Well-being 19.5 ±6.5 19.7 ± 6.5 n.s. 19.5 ± 5.4 n.s.
MSFC (Z-composite) (N = 55) - 0.162 ±0.764 −0.155 ± 0.763 n.s. - 0.120 ±0.985 n.s.
M-FIS Sum Score (N = 52) 37.9 ±18.1 37.4 ±21.4 n.s. 36.1 ±20.6 n.s.
BDI Sum Score (N = 55) 14.4 ±9.8 14.8 ±10.0 n.s. 14.6 ±8.9 n.s.
% (n) % (n) % (n)
Normal (0–8 pts) 30.9 (17) 32.7 (18) 25.5 (14)
Minimal (9–13 pts) 27.3 (15) 21.8 (12) 14.5 (8)
Mild (14–19 pts) 20.0 (11) 23.7 (13) 21.8 (12)
Medium (20–28 pts) 14.5 (8) 10.9 (6) 32.7 (18)
Severe (29–63 pts) 7.3 (4) 10.9 (6) 5.5 (3)
EDSS Extended Disability Symptom Scale, EQ-5D EuroQoL, EQ VAS Visual Analogue Scale, FAMS Functional Assessment in Multiple Sclerosis, MSFC Multiple
Sclerosis Functional Composite, M-FIS Modified Fatigue Impact Scale, BDI-II Beck Depression Inventory.
Changes from baseline to either 6 months or 12 months did not reach statistical significance (p > 0.10, Pillai’s Trace) except for EDSS at 12 months.
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MSFC z-scores indicating that disease severity is associ-
ated with depressive symptoms (p = 0.032, r = −0.190).
PASAT scores (below the 5th percentile) revealed 71 pa-
tients (49.3%) with cognitive impairment with no significant
difference between genders. A total of 24 (16.7%) patients
had pain syndromes, and 4.2% suffered from anxiety.
Fatigue was also a common symptom, reported by
63.2% (n = 91) of the patients. The mean score of the
M-FIS at baseline was 36.5 (SD: 18.5).
Patient-reported health status was assessed by the MS-
specific FAMS and the generic EuroQol instrument. The
mean total score of the FAMS was 113 (SD: 34) at base-
line. The FAMS sum score and all of its sub-scores except
family/social well-being were significantly positively corre-
lated with disease severity, as measured by MSFC.
At the 12-month follow-up, no significant change was
observed in the FAMS sum score or in any of its subscales.
The EQ-5D index score was 0.77 (SD: 0.23) at base-
line. The mean score on the EQ VAS was 62.0 (SD: 20).
The EQ VAS of MS patients differed considerably fromthat of the general population, as depicted in Figure 1.
Neither measure showed any change after one year
(Figure 2).
We also analysed negative effects on the dimensions
measured by the EQ-5D questionnaire (Table 3, Figure 2).
In each dimension, MS patients reported problems more
frequently than the general population. Approximately
60% reported problems with mobility (vs. 16% in the ge-
neral population); 20% had problems with self-care (vs.
3%); 65% had problems with usual activities (vs. 10%); 70%
suffered from pain (vs. 28%); and 56% had problems with
anxiety and/or depression. No significant difference be-
tween genders was observed, except in self-care: 23% of
male MS patients had problems with self-care, whereas
only 14% of female patients reported such problems. Fur-
thermore, we used univariate and multivariate analyses to
determine whether demographic data such as disease sub-
type, age, and/or gender predict reported impairments in
the EQ-5D dimensions. RRMS, SPMS, and age were sig-
nificant predictors of problems with mobility, self-care,




















General population MS out patients
Figure 1 Mean EQ VAS score for age-grouped MS patients ranking their health status using the EQ VAS compared to a representative
sample of the German general population [26].
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of the demographic variables predicted problems with the
EQ-5D dimension “pain”. Gender was significantly corre-
lated with problems in the dimension “usual activities”.
Next, the impact of clinical symptoms and socioeco-
nomic variables on health status were analysed in multi-
variate regression analyses (Table 4). The regression
models fit the data well to identify predictor of health sta-
tus in terms of FAMS and EQ-5D. M-FIS, BDI-II, MSFC
and EDSS were identified as significant predictors in
multivariate analyses. Higher scores in M-FIS, BDI-II, and
EDSS predicted lower scores in FAMS and EQ-5D while
lower scores in MFSC predicted lower scores in FAMSFigure 2 Quality of life parameters from baseline to month 6 and mo
and after 6 and 12 months (n = 55)). Changes from baseline to either 6
(p > 0.18, Pillai’s Trace).and EQ-5D. Socioeconomic and socio-demographic pa-
rameters such as working status, family status, number of
household inhabitants, age, and gender did not prove sig-
nificant in multivariate analyses.
Discussion
This prospective study evaluated the impact of MS on
health status using the generic EuroQol instrument and
the disease-specific measure FAMS. In line with previous
studies, we have shown that MS substantially affects health
status (Figure 1; for a review, see [5]).
Many health-status assessments have focused on MS
patients, but our study aimed to address three particularnth 12 (subjective assessment of the EQ-5D domains at baseline
months or 12 months did not reach statistical significance
Table 3 Percentage of age-grouped individuals with problems in the different EQ-5D dimensions
Mobility Self-care Usual activities Pain Anxiety/depression
Tot. M F Tot. M F Tot. M F Tot. M F Tot. M F
Gen. Pop.1 [%] 15.9 14.9 16.8 2.8 2.2 3.4 9.9 8.9 10.7 27.6 24.9 30.0 4-3 3.6 4.9
MS2 [%] 60.4 55.6 62.6 19.4 22.2 18.2 65.3 62.2 66.7 69.4 62.2 72.7 56.3 44.4 61.6
UV OR [CI] MV OR [CI] UV OR [CI] MV OR [CI] UV OR [CI] MV OR [CI] UV OR [CI] MV OR [CI] UV OR [CI] MV OR [CI]
RRMS§ .077** [.026;.232] n.s. .07** [.04;.25] n.s. .10** [.03;.31] n.s. n.s. n.s. n.s. 17.92*
[1.50;214.83]
SPMS 8.92** [2.96;26.87] n.s. 8.14** [3.29;20.15] n.s. 9.72** [2.82;33.57] n.s. n.s. n.s. n.s. 22.83*
[1.94;269.30]
Age 1.11** [1.07;1.15] n.s. 1.11** [1.06;1.16] n.s. 1.10** [1.03;1.10] n.s. n.s. n.s. n.s. n.s.
Gender n.s. n.s. n.s. n.s. .82** [.40;1.72] n.s. n.s. n.s. n.s. n.s.
Disease Duration 1.16** [1.08;1.25] n.s. 1.14** [1.07;1.21] n.s. 1.13* [1.05;1.21] n.s. n.s. n.s. n.s. n.s.






n.s. n.s. n.s. n.s.
MSFC z-score § .19** [.09;.37] n.s. .08** [.03;.23] n.s. .31** [.17;.58] n.s. n.s. n.s. n.s. n.s.
BDI Score n.s. n.s. n.s. n.s. 1.10** [1.05;1.15] n.s. 1.14** [1.07;1.21] n.s. 1.19** [1.12;1.28] 1.13* [1.04;1.24]
M-FIS Score 1.05** [1.03;1.08] n.s. 1.04* [1.02;1.07] n.s. 1.08** [1.05;1.10] n.s. 1.08** [1.05;1.11] 1.08**
[1.05;1.12]
1.06 ** [1.04;1.09] n.s.
FAMS Score§ .97** [.96;.99] n.s. .98* [.96;.99] n.s. .96** [.94;.97] .96** [.95;.98] .96** [.95;.98] n.s. .96** [.95;.98] .97* [.05;.99]
1,2Percentage of people having problems in the EQ-5D subdimensions: comparison between data concerning the general population [26] and the specific MS population in our study, §protecting factors, **(p < .001); *
(p < .05), n.s. not significant (p > .05).
RRMS Relapsing-Remitting MS; SPMS Secondary Progressive MS; EDSS Extended Disability Symptom Scale, MSFC Multiple Sclerosis Functional Composite; BDI-II Beck Depression Inventory; M-FIS Modified Fatigue
Impact Scale; FAMS Functional Assessment of Multiple Sclerosis; Gen. Pop.: General population; Tot.: Total; M: male; F: female.























Table 4 Analysis of predictor variables for the FAMS score, EQ-5D index score and EQ VAS
FAMS score EQ-5D index score EQ VAS
beta 95% CI for B p-value beta 95% CI for B p-value beta 95% CI for B p-value
Constant 157.067;191.542 <0.001 0.851;1.291 <0.001 65.058;101.797 <0.001
M-FIS −0.611 −1.289;-0.831 <0.001 −0,431 −0.008;-0.002 <0.001 −0.523 −0.809;-0.325 <0.001
BDI-II −0.344 −1.579;-0.759 <0.001 −0,040 −0.006;0.004 n.s. −0.094 −0.638;0.237 n.s.
MSFC (z-score) 0.104 0.480;8.680 <0.05 0,194 0.004;0.109 <0.05 0.268 3.002;11.666 0.001
EDSS −0.209 −6.129;1.411 n.s. −0.259 −0.063;-0.001 <0.05 −0.281 −5.617;-0.670 <0.05
Age 0.018 −0.251;0.360 n.s. −0.044 −0.005;0.003 n.s. 0.035 −0.263;0.393 n.s.
Gender −0.060 −10.103;1.625 n.s. −0.030 −0.88;0.060 n.s. −0.007 −6.478;5.888 n.s.
Working status −0.021 −2.166;1.325 n.s. −0.026 −0.026;0.019 n.s. −0.032 −2.269;1.470 n.s.
Family status 0.020 −2.221;3.607 n.s. −0.046 −0.048;0.026 n.s. 0.081 −1.312;4.813 n.s.
Number of household inhabitans 0.033 −0.167;0.394 n.s. 0.134 0.000;0.007 n.s. 0.101 −0.077;0.512 n.s.
R2 = 0.840 R2 = 0.420 R2 = 0.581
beta: Beta standardized linear coefficient, 95% CI: 95% confidence interval for unstandardized linear coefficients, R2: coefficient of determination.
FAMS Functional Assessment in Multiple Sclerosis; EQ-5D EuroQoL, EQ VAS Visual Analogue Scale, M-FIS Modified Fatigue Impact Scale, BDI-II Beck Depression
Inventory, MSFC: Multiple Sclerosis Functional Composite.
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tient preferences to derive QALY measures for economic
evaluation [27,28]. Second, health-status assessments
stratified by MS subtype are scarce; here, we provide
insight into the health- status differences associated with
the three different types of MS (RRMS, SPMS, PPMS) in
a well-characterised patient population. Third and most
importantly, we provide a detailed longitudinal analysis
of patient-relevant outcomes in MS.
Concerning problems in the EQ-5D domains, we show
considerable impairments in health status in our study
population compared to the general German population.
Our results, however, differ from those found in the
study by Putzki et al., as our cohort reported more prob-
lems. In our study, approximately 60% of MS patients
reported some or extreme problems with mobility (vs.




















Figure 3 Mean health utility (EQ-5D, EQ VAS) and health status (FAMwith usual activities (vs. 42%); 69% suffered from pain (vs.
50%); 56% reported problems with anxiety and depression
(vs. 52%); and 17% had problems with self-care (vs. 9%).
Although the patients in our study sample reported prob-
lems in the five dimensions more frequently, these prob-
lems were most likely less extreme, explaining the very
similar mean index scores in the two studies.
Furthermore, the influence of psychological symptoms
such as depression and fatigue on self-perceived health
status was assessed. The multivariate linear and logistic re-
gression demonstrated the importance of depression and
fatigue to self-perceived health status. Previous studies
also identified those variables as independent predictors of
health-related quality of life [29,30]. Two studies have
identified depression as the strongest determinant of im-
paired quality of life in patients with MS [31,32]. Recent

















 x 100 FAMS
 Stage
S) scores for MS patients by EDSS points.
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emphasising the necessity of considering non-disease-spe-
cific symptoms when treating patients with MS. Depres-
sion and fatigue are important facets of MS and must be
considered not as secondary outcomes, but as an integral
part of disease presentation and management.
We also confirm a strong correlation between health
status and disability level (measured by EDSS), as shown
in recent publications (for a review, see [5]) in Germany
[27]. As illustrated in Figure 3, FAMS and health-utility
measure EuroQol may not adequately distinguish among
the different degrees of disease severity (i.e., the EDSS
groups) and may therefore be inappropriate outcome mea-
sures for clinical and economic studies. Thus, we also ap-
plied the MSFC, which shows better scaling properties in
combination with health-utility measures [37,38].
We could not demonstrate any change in health-
status measurements over a 12 month observation
period in our cohort, although the EDSS changed sig-
nificantly during this time. Therefore, studies evaluating
patient-reported outcomes using the EQ-5D and FAMS
should encompass longer observation periods. Recently,
a large German study (n = 674) compared EuroQoL
health status before and 12 months following beta-
interferon treatment and detected a difference of only
0.02 pts in the EQ-5D index score; this finding is signifi-
cant but not clinically relevant [28]. The baseline value
in that study (0.75) is similar to ours (0.77).
Our study has some limitations: First, the study is
based on a convenience sample rather than an epidemio-
logical survey, and only MS patients from a specialised
university outpatient clinic were included. Therefore,
generalisations should be made cautiously. The sample
may be not representative of the German population
of MS patients or MS patients of other geographic or
ethnic origins. As patients were not evenly distributed
across levels of care, more or less severely affected pa-
tients may bias the health-status results. Very few pa-
tients in our sample have disability levels higher than
EDSS 6.5. Our results therefore apply only to patients in
levels with less pronounced disabilities. Additionally, re-
lapses may have a substantial influence on health status
and self-reported quality of life in patients with MS
[27,28]. We did not collect data on relapses and therefore
cannot exclude the possibility that patient populations
with different patterns of progression and relapse fre-
quencies may show different results. Furthermore, qua-
lity of life is a multi-faceted phenomenon influenced by
multiple other factors apart from those being measured
in this study. For example, it was recently shown that
certain patterns of visual impairment are specific to pa-
tients with MS [39,40] and considerably affect health-
related quality of life [41]. Patients attach great impor-
tance to visual functioning, which should be taken intoaccount when assessing patients with MS [42]. It is of
utmost importance to comprehensively assess factors
being related to quality of life.
In conclusion, this study is in line with previous findings
and confirms that MS has a substantial impact on the self-
perceived health status of the patients. Depression and
fatigue are major predictors of impaired health status
and should be considered integral parts of MS in dis-
ease management. We observed no significant changes
after 6 or 12 months of observation in any patient-
reported outcome used in this study. Our data may
help in estimating sample sizes for future clinical trials
using patient-reported outcomes.
Conclusion
The quality of life and health status of patients with MS,
as well as their correlation with clinical and socio-
demographic outcomes, were comprehensively assessed
in a longitudinal study over 12 months. In addition to
an extensive and detailed clinical examination, a thor-
ough evaluation of fatigue, depression, quality of life,
and disease severity was included. MS considerably im-
pairs patients’ health status, with depression and fatigue
contributing considerably to the burden of disease.
Guidelines aiming to improve self-reported health status
should include treatment options for depression and fa-
tigue. Physicians should be aware of depression, fatigue and
other non-disease-specific parameters as comorbidities.
Future studies should consider the minimal clinical dif-
ference when health status is a primary outcome.
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